Market Context — Why This Technology, Why Now

The rising global burden of neglected tropical diseases (NTDs) and the increasing resistance to conventional antiparasitic drugs are driving urgent demand for innovative therapeutic solutions. International health organizations and governments are increasing funding for R&D in this area, creating a significant market pull for novel compounds. This technology addresses a critical gap, offering a unique opportunity for pharmaceutical companies to lead in a high-need, high-impact segment.

Key Competitive Advantages
01

Enables treatment of CNS parasitic infections by crossing the blood-brain barrier, addressing areas inaccessible to many existing drugs.

02

Offers a novel mechanism of action derived from natural polyphenols, potentially overcoming resistance in drug-resistant parasitic strains.

03

Demonstrates broad applicability, with potential efficacy against a range of parasitic diseases including trypanosomiasis, leishmaniasis, and malaria.

Market Opportunity
Parasitic Disease Therapeutics Market
$7B globally (AI est.)
Driven by increasing resistance to existing drugs, demand for alternatives due to side effects, and growing international investment in Neglected Tropical Diseases (NTDs) development.
Global pharmaceutical companies focusing on infectious diseases Biotech firms specializing in novel drug discovery Public-private partnerships for global health initiatives
Central Nervous System Disease Therapeutics Market
$120B globally (AI est.)
The technology's blood-brain barrier permeability allows for a unique positioning as a therapeutic for parasitic diseases affecting the central nervous system.
Major pharmaceutical companies with neuroscience divisions Specialty pharma companies targeting CNS disorders Research institutions developing brain-permeable compounds
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects specific curcumin analogs with antiparasitic properties, having successfully navigated examiner objections and prior art challenges against six documents. This indicates a robust and difficult-to-invalidate right, with a clearly defined scope of protection despite being limited to a single claim.

Competitive White Space

This patent focuses on specific curcumin analogs for antiparasitic treatment. White space exists for exploring these analogs in other therapeutic areas like anti-inflammatory or neurodegenerative conditions, or for developing novel drug delivery systems.

Economic Impact
~$20M/year estimated market opportunity (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

This technology could shorten R&D lead compound discovery and optimization by approximately 3 years, potentially reducing annual development costs by ~$3.5M (AI est.). Maximizing the exclusivity period until 2029 could enable earlier market entry, creating an opportunity for hundreds of millions of USD in annual sales (AI est.).

Speed to Market
2× faster than in-house development
This technology clearly discloses specific chemical structures of BBB-permeable curcumin analogs and their antiparasitic effects. This significantly shortens the lead compound selection and initial synthesis research phases, allowing for a direct transition to preclinical trials and formulation studies. With established basic mechanisms of action, development time could be reduced by approximately 3 years compared to starting compound discovery from scratch.
Competitive Positioning

X: Therapeutic Efficacy
Y: Safety & BBB Permeability

Business Models & Applications
💊 Pharmaceutical Development & Sales
In-house development, manufacturing, and sales of novel antiparasitic drugs based on this technology. Focus on establishing supply chains in regions with high unmet needs to achieve global market profitability.
🤝 Collaborative Research & Licensing
Partner with pharmaceutical companies or biotech ventures to accelerate clinical development of this technology. A licensing model aims to distribute development risks while generating royalty income.
🌍 Public Health Program Partnerships
Collaborate with international organizations like WHO or non-profit entities to improve access in parasitic disease-endemic regions. This strategy balances social contribution with brand value enhancement.
Adjacent Application Opportunities
🐶 Veterinary Medicine
Animal Parasite Control Medications
Parasitic diseases in livestock and pets cause significant economic losses and animal health issues. This technology's curcumin analogs could be applied as novel antiparasitic drugs specifically for animal parasites. Development of new products balancing safety and efficacy is anticipated, addressing a market worth billions globally.
🌿 Functional Foods & Supplements
Parasitic Disease Prevention Support
Given curcumin's natural origin, this technology could be repurposed for functional foods and supplements as a preventive approach. Market development is expected for health maintenance products, particularly in regions with hygiene challenges or for international travelers, targeting a consumer health market exceeding $100B.
🌾 Agriculture & Plant Protection
Plant Pathogen Control Solutions
Plant-parasitic nematodes and fungi cause severe damage to agricultural production. Applying this technology's antiparasitic action to develop new pesticides or soil amendments against plant pathogens could contribute to food security, impacting a global crop protection market over $60B.
Integration Roadmap — Estimated 41-Month Deployment
Phase 1: Preclinical Evaluation & Optimization
Duration: 8 months
Synthesize curcumin analogs disclosed in this patent and conduct detailed in vitro/in vivo efficacy and safety profiling. Optimize lead compounds and select candidates.
Phase 2: Clinical Trial Planning & Formulation Development
Duration: 15 months
Advance formulation research (dosage form, administration route, etc.) for selected candidate compounds and develop human clinical trial plans in consultation with regulatory authorities.
Phase 3: Regulatory Approval & Commercialization Preparation
Duration: 18 months
Submit regulatory approval applications in various countries based on clinical trial results. Simultaneously, prepare for commercialization, including establishing manufacturing systems, marketing strategies, and sales channels.
Technical Feasibility
This technology provides fundamental information on specific chemical formulas of curcumin analogs, with curcumin as a lead compound, and their synthesis methods. This allows adopting companies to quickly scale up compound production and initiate formulation research by leveraging existing organic synthesis technologies and drug development pipelines. Manufacturing is feasible with general chemical synthesis equipment, indicating high practicality without requiring substantial new capital investment.
Success Scenario
Adopting companies could leverage this technology to develop groundbreaking new drugs for parasitic diseases resistant to existing treatments. The blood-brain barrier permeability characteristic would establish a competitive advantage for therapeutics targeting the central nervous system. This is estimated to address unmet needs in global health and improve the quality of life for millions of patients annually.
Patent Record
APPLICATION NO.
JP2009-098878
REGISTRATION NO.
5495608
FILING DATE
2009/04/15
GRANT DATE
2014/03/14
EXPIRATION DATE
2029/04/15
PATENT HOLDER
国立大学法人秋田大学
Examination History
2012-04-13
Request for Examination
2012-05-22
Invitation to Amend (Intermediate Document)
2012-05-30
Amendment (Voluntary)
2013-11-12
Office Action
2013-12-25
Applicant's Response
2013-12-25
Amendment (Voluntary)
2014-02-12
Decision to Grant